US equities |
MU $1,035.84 ▼-4.79% NVDA $230.48 ▼-2.94% SNDK $1,609.46 ▼-4.90% AMD $620.68 ▼-3.90% INTC $107.08 ▼-5.34% AAPL $340.42 ▲+1.11% META $720.89 ▼-0.06% SPCX $160.57 ▼-4.19%
FinancialContent

Articles published by Optinose, Inc.

News headline image
Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Announces 1-for-15 Reverse Stock Split
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Announces Reporting Date for Third Quarter 2024 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Appoints Terry Kohler as Chief Financial Officer
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Expanded Access to XHANCE with Addition to National Commercial Formularies
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Announces $55 Million Registered Direct Offering
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose to Present at the Needham Virtual Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN
News headline image
Optinose to Present at the 2023 Cantor Global Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Tickers OPTN